|
Path/Part |
Mouse dosage |
Rat dosage |
NHP/Large Animal Dosage |
Common volumes (mice) |
First expression observation |
|
Tail vein (IV) |
1×10^11-1×10^12 vg/piece (about 5×10^12-5×10^13 vg/kg) |
CNS targeting AAV9 3×10^13-1×10^14 vg/kg |
1×10^12-6×10^13 vg/kg (system IV) |
100-300 μL |
2-6 weeks |
|
Retroorbital vein (RO) |
1×10^11-2×10^12 vg/only |
Generally not recommended |
— |
100-150 μL |
2-6 weeks |
|
Portal vein (PV) |
1×10^10-1×10^12 vg/only |
1×10^11-1×10^12 vg/only |
~10^12-10^13 vg/kg (historical plan, to be verified) |
≤100 μL |
2-6 weeks |
|
Intraperitoneal cavity (IP) |
1×10^11-1×10^12 vg/only |
2×10^11 vg/only |
— |
100-200 μL |
2-6 weeks |
|
Subcutaneous (SC) |
5×10^10-4×10^11 vg/only |
To be verified (approximately 1×10^12 vg/kg level) |
~10^12 vg level/part (to be verified) |
~100 μL/dot |
≥6 months |
|
Intramuscular (IM) |
1×10^9-1×10^11 vg/muscle; total multiple muscles 1×10^11-1×10^12 |
~1×10^11 vg/muscle |
rhesus IM AAV8 3×10^12 GC/kg |
25-50 μL/dot |
2-6 weeks |
|
Brain stereotaxy |
1×10^9-1×10^10 vg/site |
2×10^10-6×10^10 vg/site |
1.5×10^11 vg/brain (putamen) |
0.2-2 μL/site |
3-4 weeks |
|
Ventricles (neonatal/adult ICV) |
Newborn 1-2×10^10 GC/hemisphere; adult 1×10^11 vg/side |
Stereotaxy of adult lateral ventricles |
4×10^13 vg (bilateral) |
Newborn 1-2 μL/side; adult 5-10 μL |
2-4 weeks |
|
Intrathecal (IT/lumbar puncture) |
5×10^10-1×10^11 vg/only |
1-2×10^11 vg |
4.8×10^12-9.2×10^13 vg/piece; same level as dog/pig |
5-10 μL |
3-6 weeks |
|
Cerebellomedullary cistern (CM/ICM) |
1×10^10-7×10^10 vg |
1×10^12 vg |
1.7-5×10^13 GC |
1-10 μL |
3-4 weeks |
|
Lumbar puncture (LP) |
Same as IT(L5-L6) |
Same as IT |
1×10^13 vg/kg; pig 1.4×10^13 GC/mL×400-800 μL |
5-10 μL |
3-6 weeks |
|
Subretinal (SR) |
1×10^8-3×10^9 vg/eye |
1×10^9-1×10^10 vg/eye |
7×10^11-7×10^12 vg/eye (AAV8); dog 1-1.4×10^11 |
1-2 μL |
3-6 weeks |
|
Intravitreal cavity (IVT) |
1×10^9-1×10^10 vg/eye |
1×10^9-5×10^9 vg/eye |
7×10^11 vg/eye |
1-2 μL |
3-6 weeks |
|
Intranasal/Intratracheal |
4×10^11-1×10^12 vg/only |
1×10^11-5×10^12 vg/only |
NHP atomization ~3 mL; sheep 10 mL/time |
25-50 μL |
1-2 weeks |
|
Renal vein/retrograde ureter |
1×10^11-1×10^12 vg/kidney |
1×10^11-5×10^11 vg/kidney |
Data is limited |
100 μL/kidney |
2-4 weeks |
|
Pancreatic duct |
2×10^11-2×10^12 vg/only (AAV6) |
To be approved |
Limited data (ERCP path) |
100 μL |
4-6 weeks |
|
Articular cavity (IA) |
0.5×10^10-1×10^11 vg/joint |
1×10^10-2.5×10^10 vg/joint |
Clinical magnitude of equine OA |
5 μL/joint |
2-4 weeks |
|
Intratumoral (ITu) |
5×10^10-1×10^11 vg/tumor |
1×10^10-5×10^10 vg/tumor |
Spontaneous tumor in dogs (to be diagnosed) |
50-100 μL/tumor |
1-2 weeks |
|
Sciatic nerve/peripheral nerve |
2.1×10^8 vg(scAAV1) |
2×10^11 GC/nerve |
2.5×10^12-2.6×10^13 vg/nerve |
2-20 μL |
3-4 weeks |
|
Cochlea/inner ear |
1×10^10-5×10^10 vg/ear |
About 2-5 μL (to be nucleated) |
1×10^11-7×10^11 vg/ear |
0.6-2 μL |
2-4 weeks |
|
Myocardial part |
5×10^10-1×10^11 vg/heart |
1×10^11-5×10^11 vg/heart |
Canine 7-Fr endocardial catheter; pig multi-site thoracotomy |
30 μL(3 points) |
3-4 weeks |
|
Fat pad |
1×10^11-2×10^11 vg/pad |
To be approved |
— |
30-50 μL |
3-4 weeks |
|
Intracutaneous/wound |
~2×10^10 vg/dot |
50-100 μL per point |
Pig skin transformation model |
10-20 μL/dot |
2-4 weeks |
CROSSILICO KNOWLEDGE CENTER
CGT Wiki
Gene and cell therapy terminology, workflows, evidence, and technical reference.
1. Quick guide to route of administration
AAV, Administration Routes, Dosing, and Expression Assessment
Updated Oct 23, 2026